184 results on '"Balog, Aaron"'
Search Results
2. Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex
3. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
4. Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1
5. Supplementary Data from Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
6. Desoxyepothilone B is Curative against Human Tumor Xenografts that are Refractory to Paclitaxel
7. Desoxyepothilone B: An Efficacious Microtubule-Targeted Antitumor Agent with a Promising in vivo Profile Relative to Epothilone B
8. Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity to Taxol and Epothilones
9. Supplementary Table 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
10. Supplementary Figure and Table Legends 1-2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
11. Data from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
12. Supplementary Table 2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
13. Supplementary Figure 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
14. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer
15. Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide
16. Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors
17. Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy
18. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
19. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1
20. Native Mass Spectrometry and Gas-Phase Fragmentation Provide Rapid and In-Depth Topological Characterization of a PROTAC Ternary Complex
21. Overcoming Bioanalytical Challenges in Support of a Discovery IDO Program
22. Novel Androgen Receptor Antagonists for the Treatment of Prostate Cancer
23. Probing the SAR of dEpoB via chemical synthesis: a total synthesis evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone
24. Drug Safety Is A Barrier to the Discovery and Development of New Androgen Receptor Antagonists
25. Total syntheses of epothilones A and
26. Additive and medium effects on Lewis acid-promoted cationic pi-cyclizations of alkenyl- and alkynylcyclopentane-1,3-diones
27. Ring-enlarging annulations. A one-step conversion of cyclic silyl acyloins omega-alkynyl acetals to polycyclic enediones
28. Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
29. [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists
30. Dianion equivalents corresponding to the polypropionate domain of epothilone B
31. Remarkable long range effects on the diastereoface selectivity in an aldol condensation
32. BMS-871: A novel orally active pan-Notch inhibitor as an anticancer agent
33. Abstract 4964: Structure, in vitro biology and in vivo pharmacodynamic characterization of a novel clinical IDO1 inhibitor
34. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer
35. Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
36. Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
37. Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies
38. Abstract 1643: BMS-983970, an oral pan-Notch inhibitor for the treatment of cancer
39. Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.02,6]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists
40. Synthesis of [3α‐3H] 17α‐Hydroxy pregnenolone and [3α‐3H] Pregnenolone
41. Remote effects in macrolide formation through ring-forming olefin metathesis: an application to the synthesis of fully active epothilone congeners
42. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists
43. Annulative ring expansions. Direct conversion of omega-alkynyl acetals to polycyclic unsaturated ketones
44. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
45. Abstract 5782: Androgen receptor antagonists: Lead optimization and preclinical pharmacology
46. Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
47. The Synthesis and Evaluation of [2.2.1]‐Bicycloazahydantoins as Androgen Receptor Antagonists.
48. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus
49. Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists
50. The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.